Abstract
Acromegaly is associated with insulin resistance and an increased incidence of cardiovascular disease. However, it remains unclear to what extent the effects of growth hormone (GH) excess on cardiovascular morbidity and mortality are mediated through insulin resistance versus through other direct or indirect effects of GH. Adequate control of GH excess by surgery or pharmacologic interventions is associated with decreased insulin resistance, reflected in decreased plasma insulin levels and fasting glucose levels or improved glucose tolerance. Despite divergent effects of both somatostatin and somatostatin analogs on GH, insulin and glucagon secretion, and glucose absorption, treatment with the somatostatin analogs octreotide and lanreotide has only limited effects on glucose metabolism. However, glucose sensitivity has only been formally examined using a hyperinsulinemic euglycemic clamp in a minority of these studies. Treatment with the GH-receptor antagonist pegvisomant ameliorates insulin sensitivity, reflected in decreased fasting plasma insulin levels and fasting glucose levels. Nonetheless, the effect of pegvisomant on glucose sensitivity has not been formally tested by hyperinsulinemic clamp conditions. In acromegaly, preliminary observations on new octreotide analogs with greater specificity for somatostatin-receptor subtypes indicate that these compounds achieve better control of GH hypersecretion than octreotide, but may also negatively influence insulin release. Assessment of insulin secretion and glucose levels in acromegalic patients during administration of these compounds is thus mandatory.
Similar content being viewed by others
Notes
The use of trade names is for product identification purposes only and does not imply endorsement.
References
Orme SM, McNally RJ, Cartwright RA, et al. Mortality and cancer incidence in acromegaly: a retrospective cohort study. United Kingdom Acromegaly Study Group. J Clin Endocrinol Metab 1998; 83(8): 2730–4
Adler AI, Neil HA, Manley SE, et al. Hyperglycemia and hyperinsulinemia at diagnosis of diabetes and their association with subsequent cardiovascular disease in the United Kingdom Prospective Diabetes Study (UKPDS 47). Am Heart J 1999; 138 (5 Pt 1): S353–9
Rajasoorya C, Holdaway IM, Wrightson P, et al. Determinants of clinical outcome and survival in acromegaly. Clin Endocrinol (Oxf) 1994; 41(1): 95–102
de Vegt F, Dekker JM, Stehouwer CD, et al. Similar 9-year mortality risks and reproducibility for the World Health Organization and American Diabetes Association glucose tolerance categories: the Hoorn Study. Diabetes Care 2000; 23(1): 40–4
Lakka HM, Laaksonen DE, Lakka TA, et al. The metabolic syndrome and total and cardiovascular disease mortality in middle-aged men. JAMA 2002; 288(21): 2709–16
Roelfsema F, Frolich M. Glucose tolerance and plasma immunoreactive insulin levels in acromegalics before and after selective transsphenoidal surgery. Clin Endocrinol (Oxf) 1985; 22(4): 531–7
Wasada T, Aoki K, Sato A, et al. Assessment of insulin resistance in acromegaly associated with diabetes mellitus before and after transsphenoidal adenomectomy. Endocr J 1997; 44(4): 617–20
Battezzati A, Benedini S, Fattorini A, et al. Insulin action on protein metabolism in acromegalic patients. Am J Physiol Endocrinol Metab 2003; 284(4): E823–9
Freda PU, Reyes CM, Conwell IM, et al. Serum ghrelin levels in acromegaly: effects of surgical and long-acting octreotide therapy. J Clin Endocrinol Metab 2003; 88(5): 2037–44
Jaffrain-Rea ML, Minniti G, Moroni C, et al. Impact of successful transsphenoidal surgery on cardiovascular risk factors in acromegaly. Eur J Endocrinol 2003; 148(2): 193–201
Kasayama S, Otsuki M, Takagi M, et al. Impaired beta-cell function in the presence of reduced insulin sensitivity determines glucose tolerance status in acromegalic patients. Clin Endocrinol (Oxf) 2000; 52(5): 549–55
Moller N, Schmitz O, Joorgensen JO, et al. Basal- and insulin-stimulated substrate metabolism in patients with active acromegaly before and after adenomectomy. J Clin Endocrinol Metab 1992; 74(5): 1012–9
Ronchi CL, Orsi E, Giavoli C, et al. Evaluation of insulin resistance in acromegalic patients before and after treatment with somatostatin analogues. J Endocrinol Invest 2003; 26(6): 533–8
Biermasz NR, van Dulken H, Roelfsema F. Ten-year follow-up results of transsphenoidal microsurgery in acromegaly. J Clin Endocrinol Metab 2000; 85(12): 4596–602
Beauregard C, Truong U, Hardy J, et al. Long-term outcome and mortality after transsphenoidal adenomectomy for acromegaly. Clin Endocrinol (Oxf) 2003; 58(1): 86–91
Swearingen B, Barker FG, Katznelson L, et al. Long-term mortality after transsphenoidal surgery and adjunctive therapy for acromegaly. J Clin Endocrinol Metab 1998; 83(10): 3419–26
Eastman RC, Gorden P, Glatstein E, et al. Radiation therapy of acromegaly. Endocrinol Metab Clin North Am 1992; 21(3): 693–712
Biermasz NR, Dulken HV, Roelfsema F. Postoperative radiotherapy in acromegaly is effective in reducing GH concentration to safe levels. Clin Endocrinol (Oxf) 2000; 53(3): 321–7
Barrande G, Pittino-Lungo M, Coste J, et al. Hormonal and metabolic effects of radiotherapy in acromegaly: long-term results in 128 patients followed in a single center. J Clin Endocrinol Metab 2000; 85(10): 3779–85
Lamberts SW, Uitterlinden P, Verschoor L, et al. Long-term treatment of acromegaly with the somatostatin analogue SMS 201-995. N Engl J Med 1985 Dec 19; 313(25): 1576–80
Lamberts SW, Oosterom R, Neufeld M, et al. The somatostatin analog SMS 201-995 induces long-acting inhibition of growth hormone secretion without rebound hypersecretion in acromegalic patients. J Clin Endocrinol Metab 1985; 60(6): 1161–5
Heron I, Thomas F, Dero M, et al. Pharmacokinetics and efficacy of a long-acting formulation of the new somatostatin analog BIM 23014 in patients with acromegaly. J Clin Endocrinol Metab 1993; 76(3): 721–7
Stewart PM, Kane KF, Stewart SE, et al. Depot long-acting somatostatin analog (Sandostatin LAR®) is an effective treatment for acromegaly. J Clin Endocrinol Metab 1995; 80(11): 3267–72
Trainer PJ, Drake WM, Katznelson L, et al. Treatment of acromegaly with the growth hormone-receptor antagonist pegvisomant. N Engl J Med 2000 Apr 20; 342(16): 1171–7
Matthews DR, Hosker JP, Rudenski AS, et al. Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia 1985; 28(7): 412–9
Kuhn JM, Basin C, Mollard M, et al. Effects of the new somatostatin analogue (BIM 23014) on blood glucose homeostasis in normal men. Eur J Clin Invest 1992; 22(12): 793–9
Rizza RA, Mandarino LJ, Gerich JE. Effects of growth hormone on insulin action in man: mechanisms of insulin resistance, impaired suppression of glucose production, and impaired stimulation of glucose utilization. Diabetes 1982; 31 (8 Pt 1): 663–9
Rosenfeld RG, Wilson DM, Dollar LA, et al. Both human pituitary growth hormone and recombinant DNA-derived human growth hormone cause insulin resistance at a postreceptor site. J Clin Endocrinol Metab 1982; 54(5): 1033–8
Bratusch-Marrain PR, Smith D, DeFronzo RA. The effect of growth hormone on glucose metabolism and insulin secretion in man. J Clin Endocrinol Metab 1982; 55(5): 973–82
Costa C, Solanes G, Visa J, et al. Transgenic rabbits overexpressing growth hormone develop acromegaly and diabetes mellitus. FASEB J 1998; 12(14): 1455–60
Rossetti L, Frontoni S, Dimarchi R, et al. Metabolic effects of IGF-1 in diabetic rats. Diabetes 1991; 40(4): 444–8
Boulware SD, Tamborlane WV, Rennert NJ, et al. Comparison of the metabolic effects of recombinant human insulin-like growth factor-1 and insulin: dose-response relationships in healthy young and middle-aged adults. J Clin Invest 1994; 93(3): 1131–9
Yakar S, Liu JL, Fernandez AM, et al. Liver-specific IGF-1 gene deletion leads to muscle insulin insensitivity. Diabetes 2001; 50(5): 1110–8
Sjogren K, Wallenius K, Liu JL, et al. Liver-derived IGF-1 is of importance for normal carbohydrate and lipid metabolism. Diabetes 2001; 50(7): 1539–45
Yakar S, Setser J, Zhao H, et al. Inhibition of growth hormone action improves insulin sensitivity in liver IGF-1-deficient mice. J Clin Invest 2004; 113(1): 96–105
Hussain MA, Schmitz O, Mengel A, et al. Insulin-like growth factor-1 stimulates lipid oxidation, reduces protein oxidation, and enhances insulin sensitivity in humans. J Clin Invest 1993; 92(5): 2249–56
Garcia Lopez JM, De la Fuente A, Tome MA, et al. Acromegaly and insulin resistance: a case study. Acta Endocrinol (Copenh) 1986; 111(4): 445–51
Garcia-Estevez DA, Araujo-Vilar D, Cabezas-Cerrato J. Non-insulin-mediated glucose uptake in several insulin-resistant states in the postabsortive period. Diabetes Res Clin Pract 1998; 39(2): 107–13
Cerasi E, Luft R. Insulin response to glucose loading in acromegaly. Lancet 1964; 15: 769–71
Luft R, Cerasi E, Hamberger CA. Studies on the pathogenesis of diabetes in acromegaly. Acta Endocrinol (Copenh) 1967; 56(4): 593–607
Sonksen PH, Greenwood FC, Ellis JP, et al. Changes of carbohydrate tolerance in acromegaly with progress of the disease and in response to treatment. J Clin Endocrinol Metab 1967; 27(10): 1418–30
Wass JA, Cudworth AG, Bottazzo GF, et al. An assessment of glucose intolerance in acromegaly and its response to medical treatment. Clin Endocrinol (Oxf) 1980; 12(1): 53–9
Lawrence JH, Tobias CA, Linfoot JA, et al. Successful treatment of acromegaly: metabolic and clinical studies in 145 patients. J Clin Endocrinol Metab 1970; 31(2): 180–98
Hansen I, Tsalikian E, Beaufrere B, et al. Insulin resistance in acromegaly: defects in both hepatic and extrahepatic insulin action. Am J Physiol 1986; 250 (3 Pt 1): E269–73
Foss MC, Saad MJ, Paccola GM, et al. Peripheral glucose metabolism in acromegaly. J Clin Endocrinol Metab 1991; 72(5): 1048–53
Ezzat S, Forster MJ, Berchtold P, et al. Acromegaly: clinical and biochemical features in 500 patients. Medicine (Baltimore) 1994; 73(5): 233–40
Koop BL, Harris AG, Ezzat S. Effect of octreotide on glucose tolerance in acromegaly. Eur J Endocrinol 1994; 130(6): 581–6
Colao A, Ferone D, Cappabianca P, et al. Effect of octreotide pretreatment on surgical outcome in acromegaly. J Clin Endocrinol Metab 1997; 82(10): 3308–14
Colao A, Baldelli R, Marzullo P, et al. Systemic hypertension and impaired glucose tolerance are independently correlated to the severity of the acromegalic cardiomyopathy. J Clin Endocrinol Metab 2000; 85(1): 193–9
Fontbonne AM, Eschwege EM. Insulin and cardiovascular disease: Paris Prospective Study. Diabetes Care 1991; 14(6): 461–9
de Simone G, Devereux RB, Palmieri V, et al. Relation of insulin resistance to markers of preclinical cardiovascular disease: the Strong Heart Study. Nutr Metab Cardiovasc Dis 2003; 13(3): 140–7
Hanley AJ, Williams K, Stern MP, et al. Homeostasis model assessment of insulin resistance in relation to the incidence of cardiovascular disease: the San Antonio Heart Study. Diabetes Care 2002; 25(7): 1177–84
Anand SS, Yi Q, Gerstein H, et al. Relationship of metabolic syndrome and fibrinolytic dysfunction to cardiovascular disease. Circulation 2003; 108(4): 420–5
Patel YC, Greenwood MT, Warszynska A, et al. All five cloned human somatostatin receptors (hSSTRl-5) are functionally coupled to adenylyl cyclase. Biochem Biophys Res Commun 1994; 198(2): 605–12
Lamberts SW, van der Lely AJ, de Herder WW, et al. Octreotide. N Engl J Med 1996; 334(4): 246–54
Davies RR, Miller M, Turner SJ, et al. Effects of somatostatin analogue SMS 201-995 in normal man. Clin Endocrinol (Oxf) 1986; 24(6): 665–74
Lamberts SW, Verleun T, Zuiderwijk JM, et al. The effect of the somatostatin analog SMS 201-995 on normal growth hormone secretion in the rat: a comparison with the effect of bromocriptine on normal prolactin secretion. Acta Endocrinol (Copenh) 1987; 115(2): 196–202
Krejs GJ, Browne R, Raskin P. Effect of intravenous somatostatin on jejunal absorption of glucose, amino acids, water, and electrolytes. Gastroenterology 1980; 78(1): 26–31
Barnard LB, Grantham WG, Lamberton P, et al. Treatment of resistant acromegaly with a long-acting somatostatin analogue (SMS 201-995). Ann Intern Med 1986; 105(6): 856–61
Vance ML, Harris AG. Long-term treatment of 189 acromegalic patients with the somatostatin analog octreotide: results of the International Multicenter Acromegaly Study Group. Arch Intern Med 1991; 151(8): 1573–8
James RA, Moller N, Chatterjee S, et al. Carbohydrate tolerance and serum lipids in acromegaly before and during treatment with high-dose octreotide. Diabet Med 1991; 8(6): 517–23
Ho KK, Jenkins AB, Furier SM, et al. Impact of octreotide, a long-acting somatostatin analogue, on glucose tolerance and insulin sensitivity in acromegaly. Clin Endocrinol (Oxf) 1992; 36(3): 271–9
Sato K, Takamatsu K, Hashimoto K. Short-term effects of octreotide on glucose tolerance in patients with acromegaly. Endocr J 1995; 42(6): 739–45
Ayuk J, Stewart SE, Stewart PM, et al. Long-term safety and efficacy of depot long-acting somatostatin analogs for the treatment of acromegaly. J Clin Endocrinol Metab 2002; 87(9): 4142–6
Ezzat S, Ren SG, Braunstein GD, et al. Octreotide stimulates insulin-like growth factor-binding protein-1: a potential pituitary-independent mechanism for drug action. J Clin Endocrinol Metab 1992; 75(6): 1459–63
Breidert M, Pinzer T, Wildbrett J, et al. Long-term effect of octreotide in acromegaly on insulin resistance. Horm Metab Res 1995; 27(5): 226–30
Arosio M, Machelli S, Rossi CM, et al. Effects of treatment with octreotide in acromegalic patients: a multicenter Italian study. Italian Multicenter Octreotide Study Group. Eur J Endocrinol 1995; 133(4): 430–9
Giusti M, Gussoni G, Cuttica CM, et al. Effectiveness and tolerability of slow release lanreotide treatment in active acromegaly: six-month report on an Italian multicenter study. Italian Multicenter Slow Release Lanreotide Study Group. J Clin Endocrinol Metab 1996; 81(6): 2089–97
van der Lely AJ, Hutson RK, Trainer PJ, et al. Long-term treatment of acromegaly with pegvisomant, a growth hormone receptor antagonist. Lancet 2001; 358(9295): 1754–9
Rose DR, Clemmons DR. Growth hormone receptor antagonist improves insulin resistance in acromegaly. Growth Horm IGF Res 2002; 12(6): 418–24
Ronchi C, Epaminonda P, Cappiello V, et al. Effects of two different somatostatin analogs on glucose tolerance in acromegaly. J Endocrinol Invest 2002; 25(6): 502–7
Drake WM, Rowles SV, Roberts ME, et al. Insulin sensitivity and glucose tolerance improve in patients with acromegaly converted from depot octreotide to pegvisomant. Eur J Endocrinol 2003; 149(6): 521–7
Data on file, Ipsen-Beaufour, 2000
al Maskari M, Gebbie J, Kendall-Taylor P. The effect of a new slow-release, long-acting somatostatin analogue, lanreotide, in acromegaly. Clin Endocrinol (Oxf) 1996; 45(4): 415–21
Colao A, Marzullo P, Lombardi G. Effect of a six-month treatment with lanreotide on cardiovascular risk factors and arterial intima-media thickness in patients with acromegaly. Eur J Endocrinol 2002; 146(3): 303–9
Caron P, Morange-Ramos I, Cogne M, et al. Three-year follow-up of acromegalic patients treated with intramuscular slow-release lanreotide. J Clin Endocrinol Metab 1997; 82(1): 18–22
Chanson P, Boerlin V, Ajzenberg C, et al. Comparison of octreotide acetate LAR and lanreotide SR in patients with acromegaly. Clin Endocrinol (Oxf) 2000; 53(5): 577–86
Kendall-Taylor P, Miller M, Gebbie J, et al. Long-acting octreotide LAR compared with lanreotide SR in the treatment of acromegaly. Pituitary 2000; 3(2): 61–5
Cozzi R, Dallabonzana D, Attanasio R, et al. A comparison between octreotide-LAR and lanreotide-SR in the chronic treatment of acromegaly. Eur J Endocrinol 1999; 141(3): 267–71
Turner HE, Vadivale A, Keenan J, et al. A comparison of lanreotide and octreotide LAR for treatment of acromegaly. Clin Endocrinol (Oxf) 1999; 51(3): 275–80
Caron P, Beckers A, Cullen DR, et al. Efficacy of the new long-acting formulation of lanreotide (lanreotide Autogel®) in the management of acromegaly. J Clin Endocrinol Metab 2002; 87(1): 99–104
Data on file, Ipsen-Beaufour, 2002
Lancranjan I, Bruns C, Grass P, et al. Sandostatin LAR®: a promising therapeutic tool in the management of acromegalic patients. Metabolism 1996; 45(8 Suppl. 1): 67–71
van Thiel SW, Romijn JA, Biermasz NR, et al. Octreotide long-acting repeatable and lanreotide Autogel® are equally effective in controlling growth hormone secretion in acromegalic patients. Eur J Endocrinol 2004 Apr; 150(4): 489–95
Saveanu A, Gunz G, Dufour H, et al. BIM-23244, a somatostatin receptor subtype 2- and 5-selective analog with enhanced efficacy in suppressing growth hormone (GH) from octreotide-resistant human GH-secreting adenomas. J Clin Endocrinol Metab 2001; 86(1): 140–5
Kumar U, Sasi R, Suresh S, et al. Subtype-selective expression of the five somatostatin receptors (hSSTRl-5) in human pancreatic islet cells: a quantitative double-label immunohistochemical analysis. Diabetes 1999; 48(1): 77–85
Strowski MZ, Parmar RM, Blake AD, et al. Somatostatin inhibits insulin and glucagon secretion via two receptor subtypes: an in vitro study of pancreatic islets from somatostatin receptor 2 knockout mice. Endocrinology 2000; 141(1): 111–7
Brans C, Lewis I, Briner U, et al. SOM 230: a novel somatostatin peptidomimetic with broad somatotropin release inhibiting factor (SRIF) receptor binding and a unique antisecretory profile. Eur J Endocrinol 2002; 146(5): 707–16
Weckbecker G, Briner U, Lewis I, et al. SOM 230: a new somatostatin peptidomimetic with potent inhibitory effects on the growth hormone/insulin-like growth factor-1 axis in rats, primates, and dogs. Endocrinology 2002; 143(10): 4123–30
Van Der HJ, de Herder WW, Feelders RA, et al. A single-dose comparison of the acute effects between the new somatostatin analog SOM 230 and octreotide in acromegalic patients. J Clin Endocrinol Metab 2004; 89(2): 638–45
Ross RJ, Leung KC, Maamra M, et al. Binding and functional studies with the growth hormone receptor antagonist, B2036-PEG (pegvisomant), reveal effects of pegylation and evidence that it binds to a receptor dimer. J Clin Endocrinol Metab 2001; 86(4): 1716–23
Thorner MO, Strasburger CJ, Wu Z, et al. Growth hormone (GH) receptor blockade with a PEG-modified GH (B2036-PEG) lowers serum insulin-like growth factor-1 but does not acutely stimulate serum GH. J Clin Endocrinol Metab 1999; 84(6): 2098–103
Muller AF, Leebeek FW, Janssen JA, et al. Acute effect of pegvisomant on cardiovascular risk markers in healthy men: implications for the pathogenesis of atherosclerosis in GH deficiency. J Clin Endocrinol Metab 2001; 86(11): 5165–71
Parkinson C, Drake WM, Roberts ME, et al. A comparison of the effects of pegvisomant and octreotide on glucose, insulin, gastrin, cholecystokinin, and pancreatic polypeptide responses to oral glucose and a standard mixed meal. J Clin Endocrinol Metab 2002; 87(4): 1797–804
Acknowledgments
No sources of funding were used to assist in the preparation of this review. The authors have no conflicts of interest that are directly relevant to the content of this review.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Pereira, A.M., Biermasz, N.R., Roelfsema, F. et al. Pharmacologic Therapies for Acromegaly. Mol Diag Ther 4, 43–53 (2005). https://doi.org/10.2165/00024677-200504010-00005
Published:
Issue Date:
DOI: https://doi.org/10.2165/00024677-200504010-00005